VISIT OUR COVID-19 HUB

Our Science
GettyImages-1208505315_790x500_1_0.png
GettyImages-1208505315_1000x450_0_0_0.jpg

VISIT OUR COVID-19 HUB

Sharing resources to stay safe and updates on our efforts we hope could bring an end to the global health crisis.

Learn More

Aiming for Equity

Our Purpose
Pfizer-Equity-Diversity_380x500.png
Pfizer-Equity-Diversity_1000x450.jpg

Aiming for Equity

In 2020, CEO Albert Bourla laid out a series of goals to demonstrate Pfizer’s dedication to Equity by increasing diversity and inclusion. Here’s the progress that’s been made.

Learn More

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine

Our Science
young_woman_getting_vaccinated_380x500_0.png
young_woman_getting_vaccinated_1000x450_0.jpg

The Facts About Pfizer and BioNTech’s COVID-19 Vaccine

The U.S. FDA authorization of the Pfizer-BioNTech COVID-19 vaccine for emergency use is a significant step forward in our fight against this pandemic.

Learn More

TRANSLATING TECHNICAL LANGUAGE INTO PLAIN LANGUAGE FOR CLINICAL TRIALS

Your Health
clinical_trial_results_790X500_v2.jpg
clinical_trial_results_1000X450.jpg

TRANSLATING TECHNICAL LANGUAGE INTO PLAIN LANGUAGE FOR CLINICAL TRIALS

Making clinical trial results easier for everyone to understand is one way Pfizer demonstrates a commitment to health equity.

LEARN MORE

Search products

Search products, A–Z

Need help paying for Pfizer medicines?

pfizer-logo
Your search for a clinical trial starts here.
Learn more about the process of joining a clinical trial and find a trial near you.
Start now

LEARN ABOUT OUR CLINICAL TRIAL FOR PEOPLE RECENTLY DIAGNOSED WITH COVID-19

Our Science
learn_about_our_clinical_trial_380x500_0.png
learn_about_our_clinical_trial_1000x450.jpg

LEARN ABOUT OUR CLINICAL TRIAL FOR PEOPLE RECENTLY DIAGNOSED WITH COVID-19

Do you have COVID-19? We are currently enrolling participants in a clinical trial for a potential oral treatment option.

See If You Qualify

A NEW PARTNERSHIP THAT TARGETS RARE DISEASE

Our Purpose
through_public_private_partnership_790x500.png
through_public_private_partnership_1000x450.jpg

A NEW PARTNERSHIP THAT TARGETS RARE DISEASE

This five-year endeavor brings together a consortium of 30 to explore using advanced therapy medicinal products to treat rare diseases.

READ ON

Latest News

Positive Top-Line Results From Pfizer’s Phase 3…

-JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies- Pfizer Inc. (NYSE: PFE) today announced that JADE DARE (B7451050), a 26-week, randomized, double-blind, double-dummy, active-controlled, multi-center Phase 3 study, met its co-primary and key secondary efficacy endpoints. The study showed that abrocitinib was statistically superior compared to dupilumab in each evaluated efficacy measure and had a safety profile…
Read more